Results 21 to 30 of about 178,284 (250)

Subcutaneous administration of the malaria R21/Matrix M vaccine and immune complex formation with anti-circumsporozoite protein mAb 2A10 elicit protective efficacy in mice [PDF]

Frontiers in Immunology
IntroductionR21, the most efficacious malaria vaccine to date, has been recommended by the World Health Organization (WHO) for the prevention of malaria in children. The current vaccination schedule requires three intramuscular doses per year. Optimizing
Ekta Mukhopadhyay, César López Camacho, Adrian V. S. Hill, Ahmed M. Salman   +3 more
doaj   +3 more sources

R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial

Frontiers in Immunology
IntroductionThe recently licenced R21/Matrix-M vaccine induces a protective antibody response. In this study, we examined vaccine-induced responses in semi-immune adults in a controlled human malaria infection (CHMI) Phase IIb clinical trial ...
Elizabeth Kibwana, Caroline Bundi, Domtila Kimani, Lydia Nyamako, Kelvias Keter, Agnes Mutiso, Rodney Ogwang, Duncan Bellamy, Katerina Rapi, Amelia Bajer, Samuel Provstgaard-Morys, Lisa Stockdale, Olivia Munoz, Mehreen S. Datoo, Alison Lawrie, Fernando Ramos-Lopez, Rachel Roberts, Mainga Hamaluba, Mainga Hamaluba, Adrian V. S. Hill, Philip Bejon, Philip Bejon, Katie J. Ewer, Melissa Kapulu, Melissa Kapulu   +24 more
doaj   +4 more sources

Awareness, acceptability, and willingness to pay for the R21/Matrix-M malaria vaccine: a cross-sectional study among pregnant women and nursing mothers in Enugu State, Nigeria [PDF]

BMC Public Health
Background The R21/Matrix-M vaccine has significantly reduced incident malaria in children aged 3–36 months, but awareness, acceptance, and affordability of the vaccine are key to its successful rollout.
Uzochukwu Emmanuel Chima, Abdulmuminu Isah, Isah Abdulmuminu   +2 more
exaly   +3 more sources

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

Lancet, The, 2021
Summary Background Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 12 months in ...
Ousmane Traoré, Duncan Bellamy, Karim Derra   +2 more
exaly   +2 more sources

Systematic Development and Validation of a Bradford-Based Protein Quantification Method for Novel Multi-Dose R21 Malaria Vaccine Formulated with 2-Phenoxy Ethanol (2-PE). [PDF]

Vaccines (Basel)
Background: The R21 malaria vaccine is a next-generation, WHO-prequalified vaccine that was introduced to reduce the burden of clinical malaria. In alignment with WHO recommendations, multi-dose vaccine presentations are preferred for large-scale ...
Jena R, Ranade D, Chaudhari P, Salunke A, Mahamuni A, Gairola S.   +5 more
europepmc   +2 more sources

Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms

Cell Reports Medicine, 2023
Summary Adjuvanted protein vaccines offer high efficacy, yet most potent adjuvants remain proprietary. Several adjuvant compounds are being developed by the Vaccine Formulation Institute in Switzerland for global open access clinical use.
Sören Reinke, Eirini Pantazi, G. Chappell, Alexandra Sánchez-Martínez, Romain Guyon, J. Fergusson, A. Salman, A. Aktar, E. Mukhopadhyay, Roland Ventura, F. Auderset, Patrice M. Dubois, Nicolas Collin, Adrian V. S. Hill, Jelena S. Bezbradica, A. Milicic   +15 more
semanticscholar   +3 more sources

Genome Sequencing and Analysis of the Postharvest Fungus Penicillium expansum R21 [PDF]

Genome Announcements, 2017
ABSTRACT Blue mold is the vernacular name of a common postharvest disease of stored apples, pears, and quince that is caused by several common species of Penicillium . This study reports the draft genome sequence of Penicillium expansum strain R21, which was isolated from a red ...
Guohua Yin, Yuliang Zhang, Sui Sheng T. Hua, Jiujiang Yu, Lijing Bu, Kayla K. Pennerman, Qixing Huang, Anping Guo, Joan W. Bennett   +8 more
openaire   +3 more sources

R21/Matrix-M vaccine: optimising supply, maximising impact

Lancet, The
Chukwudi A Nnaji, Charles S Wiysonge
exaly   +4 more sources

Roll out and prospects of the malaria vaccine R21/Matrix-M

PLOS Medicine
In this Perspective article, Lorenz von Seidlein outlines the promise of two malaria vaccines, and discusses some of the considerations for their roll out.
L. Seidlein
openaire   +4 more sources

Public health impact of catch-up vaccination or additional booster doses with pre-erythrocytic malaria vaccine R21/Matrix-M: a modelling study. [PDF]

BMC Med
Background The pre-erythrocytic malaria vaccine R21/Matrix-M is recommended for young children, who often bear the highest burden, in malaria endemic regions.
McCain K, Topazian HM, Challenger JD, Okell L, Winskill P, Ghani AC.   +5 more
europepmc   +2 more sources